<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data</h1>

    <table>
      <tr><th>Ticker</th><td>ENVB</td></tr>
      <tr><th>Float</th><td>820 k</td></tr>
      <tr><th>IO</th><td>30.92%</td></tr>
      <tr><th>MC</th><td>3.2 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Enveric Biosciences (NASDAQ: ENVB) reported proprietary BRET assay data showing its lead candidate EB-003 engages both Gq- and β-arrestin–mediated signaling downstream of the 5-HT2A receptor, with a modest bias toward β-arrestin versus serotonin. The company says both pathways are engaged at biologically relevant levels, is planning further testing (including Gi pathway assessment), and continues to advance EB-003 through IND-enabling studies as a potential non-hallucinogenic neuroplastogen for antidepressant and anxiolytic effects.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Proprietary BRET assays developed and validated in-house to characterize 5-HT2A pathway signaling</li><li>EB-003 demonstrates biologically relevant engagement of both Gq and β-arrestin signaling pathways</li><li>EB-003 shows modest preference toward β-arrestin over Gq relative to serotonin</li><li>Findings align with independent academic research suggesting mechanistic separation between therapeutic effects and hallucinations</li><li>Company is advancing EB-003 through IND-enabling studies</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>EB-003 remains in preclinical/IND-enabling stage and has not entered clinical trials</li><li>Further testing required, including assessment of the Gi pathway to evaluate hallucinogenic potential</li><li>Press release contains forward-looking statements and lists typical development, regulatory, funding, and clinical risks</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/ce4b2423-5760-4a00-9dca-b7cdd9a27aee" target="_blank">Original Article</a>
    </div>

    <div class="small">ENVB • TradersLink AI News</div>
  </div>
</body>
</html>